ATE368683T1 - Schwefel analoge von 21-hydroxy-6,19- oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss - Google Patents

Schwefel analoge von 21-hydroxy-6,19- oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss

Info

Publication number
ATE368683T1
ATE368683T1 AT01969729T AT01969729T ATE368683T1 AT E368683 T1 ATE368683 T1 AT E368683T1 AT 01969729 T AT01969729 T AT 01969729T AT 01969729 T AT01969729 T AT 01969729T AT E368683 T1 ATE368683 T1 AT E368683T1
Authority
AT
Austria
Prior art keywords
oxidoprogesterone
hydroxy
treatment
glucocorticoid excess
sulfur analogue
Prior art date
Application number
AT01969729T
Other languages
English (en)
Inventor
Gerardo Burton
Carlos Lantos
Adriana Veleiro
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE368683T1 publication Critical patent/ATE368683T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0073Sulfur-containing hetero ring
    • C07J71/0078Sulfur-containing hetero ring containing only sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01969729T 2000-09-18 2001-09-17 Schwefel analoge von 21-hydroxy-6,19- oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss ATE368683T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00119495 2000-09-18

Publications (1)

Publication Number Publication Date
ATE368683T1 true ATE368683T1 (de) 2007-08-15

Family

ID=8169775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01969729T ATE368683T1 (de) 2000-09-18 2001-09-17 Schwefel analoge von 21-hydroxy-6,19- oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss

Country Status (14)

Country Link
US (2) US7053228B2 (de)
EP (1) EP1330468B1 (de)
JP (1) JP2004509132A (de)
AT (1) ATE368683T1 (de)
AU (1) AU8988901A (de)
CA (1) CA2419887C (de)
CY (1) CY1107756T1 (de)
DE (1) DE60129725T2 (de)
DK (1) DK1330468T3 (de)
ES (1) ES2288987T3 (de)
IL (2) IL154775A0 (de)
PT (1) PT1330468E (de)
SI (1) SI1330468T1 (de)
WO (1) WO2002022647A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124289T2 (de) * 2000-09-18 2007-09-06 Applied Research Systems Ars Holding N.V. Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
DK1330468T3 (da) * 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
CN102190607A (zh) * 2010-03-15 2011-09-21 北京化工大学 一种农药除草剂中间体乙磺酰基乙腈的绿色合成方法
EP2413115A1 (de) * 2010-07-30 2012-02-01 Technische Universiteit Eindhoven Erzeugen eines Steuersignals aus akustischen Daten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
DK1136075T3 (da) 1997-09-21 2003-04-28 Schering Corp Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
EP0903146A1 (de) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
SK287653B6 (sk) * 1999-04-23 2011-05-06 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Nevodná farmaceutická kompozícia na dermálne použitie
DE60124289T2 (de) 2000-09-18 2007-09-06 Applied Research Systems Ars Holding N.V. Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
DK1330468T3 (da) 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider

Also Published As

Publication number Publication date
US7053228B2 (en) 2006-05-30
CA2419887A1 (en) 2002-03-21
DE60129725T2 (de) 2007-12-06
IL154775A0 (en) 2003-10-31
JP2004509132A (ja) 2004-03-25
CY1107756T1 (el) 2013-09-04
EP1330468A1 (de) 2003-07-30
WO2002022647A1 (en) 2002-03-21
DK1330468T3 (da) 2007-11-05
US20040029846A1 (en) 2004-02-12
CA2419887C (en) 2009-11-10
SI1330468T1 (sl) 2007-10-31
IL154775A (en) 2010-12-30
ES2288987T3 (es) 2008-02-01
EP1330468B1 (de) 2007-08-01
PT1330468E (pt) 2007-09-13
US20050222104A1 (en) 2005-10-06
AU8988901A (en) 2002-03-26
DE60129725D1 (de) 2007-09-13
US7479486B2 (en) 2009-01-20

Similar Documents

Publication Publication Date Title
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
ATE303156T1 (de) Verwendung von gnrh-analogue zur behandlung der harninkontinenz
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE50312289D1 (de) Verfahren zur Isolierung von mesenchymalen Stammzellen des Haarfollikels
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
AR023008A1 (es) 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) para tratar el exceso de glucocorticoides
ATE258791T1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE602006012115D1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE50112206D1 (de) Gelzusammensetzung auf alkoholischer basis zur behandlung von hypogonadismus durch transskrotale applikation
TR200200278T2 (tr) Kalsilitik bileşimler
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
ATE347536T1 (de) Chlorsilanblends zur behandlung von quarzfuellstoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1330468

Country of ref document: EP

EEFA Change of the company name